Galmed Pharma soars on under-the-tongue semaglutide development deal - TradingView
1 hour ago • Google News
Galmed Pharmaceuticals Ltd (GLMD)
US$ 2.2599-1.31%
Price Chart
Key Statistics
Market Cap
$ 3.66M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
104.79K
52W High
$ 15.10
52W Low
$ 1.21
Dividend Yield
0.00%
Beta
0.70
Technicals
50-Day MA
1.8701
200-Day MA
3.2398
52 Week High
15.1
52 Week Low
1.21
About GLMD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
Employees
3
Headquarters
Ramat Gan, Israel
CEO
Mr. Allen Baharaff
Latest News
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks
3 hours ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg